GYRE THERAPEUTICS, INC. (GYRE): Results of Operations and Financial Condition
GYRE THERAPEUTICS, INC. (GYRE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for
How this was made
The 30-second read
Why it matters
The most tradable elements are the affirmed FY 2026 revenue guidance range, the NMPA CDE acceptance of the F351 NDA for CHB-induced liver fibrosis, and the reported Q2 sales trajectory for ETUARY, Etorel, and Contiva.
Market read
Traders can reassess probability-weighted timelines for Gyre’s China fibrosis program and reprice near-term revenue expectations based on the affirmed FY guidance and Q2 sales mix.
What to watch
Cash decreased to $103.2M total as of June 30, 2026, and acquisition accounting (common control recast) may complicate near-term comparability and burn-rate expectations.
Background
This SEC 8-K includes Q2 2026 financial results and a business update for Gyre Therapeutics, including product sales, pipeline milestones, and the previously announced Cullgen acquisition.
Ticker impact
Gyre reported Q2 2026 results and affirmed full-year 2026 revenue guidance, alongside NMPA acceptance of its F351 NDA for CHB-induced liver fibrosis.
Moderate upside bias if investors view the affirmed guidance and NMPA acceptance as de-risking the fibrosis program; downside risk if cash burn or guidance credibility concerns emerge.
The filing provides multiple fresh, company-specific catalysts: Q2 revenue and EPS, affirmed FY revenue range, and a new regulatory milestone (NDA acceptance) plus acquisition-related pipeline expansion.
Market effects
Adds incremental signal for China fibrosis and IPF-related biopharma development timelines and regulatory throughput.
China NMPA acceptance can improve sentiment toward China clinical/regulatory pathways for US-listed small-cap biotechs.
Limited spillover beyond small-cap biotech risk appetite, unless the NDA acceptance changes perceived probability of later approvals.
Counterpoint
Affirmed guidance may already be priced in, and NDA acceptance is not the same as approval; investors may discount it without additional efficacy/safety readouts.
Key entities
- companyGyre Therapeutics, Inc.
Nasdaq-listed biopharmaceutical company reporting Q2 2026 results, affirmed FY 2026 revenue guidance, and China regulatory acceptance for F351.
- drug_programF351 (hydronidone)
Gyre’s CHB-induced liver fibrosis candidate; NDA accepted by China’s NMPA CDE in May 2026.
- acquired_companyCullgen Inc.
Acquired in an all-stock transaction valued at about $300 million; brought a degrader pipeline and leadership team into Gyre.
